Literature DB >> 10657486

Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas.

A M Moreno1, L Castilla-Guerra, M C Martínez-Torres, F Torres-Olivera, E Fernández, H Galera-Davidson.   

Abstract

AIMS: Phaeochromocytomas may produce several neuropeptides as they are considered neuroendocrine tumours. Nevertheless, studies are scarce and no clear predictive biologic value has been stablished in the case of neuropeptides expression.
METHODS: We have investigated immunohistochemically the neuropeptides expression of a serie of 36 phaeochromocytomas: 25 sporadic, seven familial type MEN (multiple endocrine neoplasm) and four familial phaeochromocytomas not associated with MEN syndrome. The reactivity for neuron-specific enolase (NSE), synaptophysin, vasoactive intestinal peptide (VIP), chromogranin A, calcitonin, ACTH, somatostatin and HMB-45 was tested according to the avidin-biotin complex (ABC) method using polyclonal antibodies.
RESULTS: Phaeochromocytomas have a multiple synthetic activity as main neuroendocrine feature. Despite phaeochromocytoma tumour cells heterogeneity chromogranin and synaptophysin are the most common neuropeptides synthesised, as they are associated with the presence of neuroendocrine storage granules. We find a statistically significant higher synthesis of corticotrophin hormone in familial phaeochromocytomas than in sporadic forms, on the contrary the synthesis of VIP is statistically associated with sporadic forms of phaeochromocytomas. We also found a direct relation of ACTH and overexpression and malignant tumours and a positive relationship between NSE and benign forms of phaeochromocytomas. Copyright 1999 Harcourt Brace & Co. Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10657486     DOI: 10.1054/npep.1999.0012

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  9 in total

Review 1.  Differential diagnosis of pheochromocytomas and paragangliomas.

Authors:  A M McNichol
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 2.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

3.  Epinephrine producing pheochromocytoma. Is the secretory pattern decisive for the clinical manifestation?

Authors:  E Lipsic; I Balazovjech; V Kosmálová; I Makaiová; J Dekrét; D F Zanou
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

Review 4.  Calcitonin: current concepts and differential diagnosis.

Authors:  Andreas Kiriakopoulos; Periklis Giannakis; Evangelos Menenakos
Journal:  Ther Adv Endocrinol Metab       Date:  2022-05-21       Impact factor: 4.435

Review 5.  [Tumors of the adrenal medulla and the paraganglia].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

6.  Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus).

Authors:  A D Miller; K Masek-Hammerman; K Dalecki; K G Mansfield; S V Westmoreland
Journal:  Vet Pathol       Date:  2009-07-15       Impact factor: 2.221

Review 7.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 8.  Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas.

Authors:  Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

9.  Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.

Authors:  Gabriele Parenti; Benedetta Zampetti; Elena Rapizzi; Tonino Ercolino; Valentino Giachè; Massimo Mannelli
Journal:  J Oncol       Date:  2012-07-17       Impact factor: 4.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.